Lv41
610 积分 2024-11-02 加入
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort
24天前
已完结
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma
24天前
已关闭
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma – clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial
2个月前
已完结
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6
2个月前
已完结
Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape
2个月前
已完结
Targeting the EGFR signalling pathway in metastatic colorectal cancer
3个月前
已完结
Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery
3个月前
已完结
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
3个月前
已完结
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response
4个月前
已完结
皖公网安备34019202002308
